



ELUTRA® CELL SEPARATION SYSTEM

WHY WAIT TO GET SERIOUS ABOUT
SEPARATION UNTIL THE MOMENT
YOU REALLY NEED IT?

**WHEN LYMPHOCYTES OR MONOCYTES ARE ON YOUR RADAR,
THE ELUTRA SYSTEM SHOULD BE AS WELL.**

Discover the Elutra system's convenient method for reliably separating cell populations into high-purity, high-yield cell products.

TERUMOBCT
Unlocking the Potential of Blood

LYMPHOCYTES

66%
RECOVERY

96%
PURITY

Powell DJ, et al., "Efficient Clinical-Scale Enrichment of Lymphocytes for Use in Adoptive Immunotherapy Using a Modified Counterflow Centrifugal Elutriation Program." *Cytotherapy* 2009; 11 (7): 923–935.

MONOCYTES

67%
RECOVERY

75%
PURITY


Read E.J., et al, NIH Department of Transfusion Medicine, Bethesda, MD; Gambro BCT, Lakewood, CO. Evaluation of a Closed Automated System to Isolate Peripheral Blood Monocytes for Dendritic Cell (DC) Immunotherapy. Ninth annual meeting of the ISCT, 29 May-1 June, 2003.

The Elutra system is a functionally closed system that uses counter-flow centrifugal elutriation—fluid flowing through cell layers in a centrifugal field—to enrich lymphocytes or monocytes based on size and density.

Setup

To perform the separation profile:

- Connect your starting cell product to the Elutra system's disposable tubing set
- Prepare and prime the tubing set
- Select the desired separation profile (optional: automated red blood cell debulking)
- Load the separation chamber with cells
- Disconnect the enriched lymphocytes or monocytes product bag from the tubing set



Results

The Elutra system is designed to return predictable lymphocyte or monocyte enrichment direct from leukapheresis products in less than one hour.

The Elutra System Delivers:

CAPABILITY – Delivers cell enrichment and depletion, all in a functionally closed system.

PURITY – Designed to provide high purity and recovery of cell populations without gradient solutions or expensive magnetic beads.

CONVENIENCE – Functionally closed, ready-to-use, disposable tubing set minimizes setup time and reduces the risk of contamination.


CONTROL – Unique conical separation chamber allows consistent processing of cellular starting material in a single run.*

VERSATILITY – Perform up to nine multi-step separation profiles with a high degree of flexibility.

* Typical results based on cell counts from a leukapheresis product collected the previous day from normal donors on a COBE® Spectra™ Apheresis System. 80 mL to 230 mL products contained 5 to 14 x 10⁹ WBC count, 80% to 100% mononuclear cell and 1.8 mL to 4.7 mL red blood cell volume.

HOW IT WORKS

The Elutra system passes fluid through the cell layer that is established within a centrifugal field inside the separation chamber to separate cells based on size and density. By varying the flow of fluid in the opposite direction of the centrifugal force, particles are aligned and collected according to size (smallest to largest) and density (lower to higher). Using both size and density as separation factors increases the resolution of cell separations achieved compared to traditional centrifugation.





TUBING SET

- 1** Separation chamber volume: 40 mL
Collection bags: 6
Plastic: non-pyrogenic, biocompatible, EtO-sterilized

USER CONFIGURABLE PROFILES

- 2** Nine: includes sample monocyte enrichment protocol

MANUAL MODE

- 3** Pumps, centrifuge speed and ramp rates fully controlled by operator

EQUIPMENT

- 4** Centrifuge speed: 300 rpm to 2,600 rpm
Pump flow rates: 0 mL/min to 150 mL/min
Elutriation media volume: 500 mL to 12,000 mL
Fraction collection capability: 12

EQUIPMENT

- 5** Weight: 177 kg (389 lb)
Height: 180.3 cm (71 in)
Width: 70 cm (27.6 in)
Depth: 68 cm (26.7 in)

LINE VOLTAGE

- 6** 100 ± 10% VAC, 50/60 Hz
115 ± 10% VAC, 50/60 Hz
230 ± 10% VAC, 50/60 Hz
240 ± 10% VAC, 50/60 Hz

INPUT LINE CURRENT

- 7** 8 A maximum RMS at 100/115 VAC
4 A maximum RMS at 230/240 VAC

Elutra disposable tubing set four per case

For more information, contact your local Terumo BCT sales representative or visit TERUMOBCT.COM/ELUTRA.

Customers are responsible for validating the use of the Elutra system to separate cells for their intended therapy.

TERUMOBCT

As a global leader in blood component, therapeutic apheresis and cellular technologies, we believe in the potential of blood to do even more for patients than it does today. This belief inspires our innovation and strengthens our collaboration with customers.

UNLOCKING THE POTENTIAL OF BLOOD | TERUMOBCT.COM

Terumo BCT, Inc.
10811 West Collins Ave.
Lakewood, Colorado 80215-4440
USA
USA Phone: 1.877.339.4228
Phone: +1.303.231.4357
Fax: +1.303.542.5215

Terumo BCT Europe N.V.
Europe, Middle East and Africa
Ikaroslaan 41
1930 Zaventem
Belgium
Phone: +32.2.715.05.90
Fax: +32.2.721.07.70

Terumo BCT (Asia Pacific) Ltd.
Room 3903-3903A, 39/F
ACE Tower, Windsor House
311 Gloucester Road
Causeway Bay, Hong Kong
Phone: +852.2283.0700
Fax: +852.2576.1311

Terumo BCT Latin America S.A.
La Pampa 1517-12th Floor
C1428DZE
Buenos Aires
Argentina
Phone: +54.11.5530.5200
Fax: +54.11.5530.5201

Terumo BCT Japan, Inc.
Takanawa Park Tower 13F
20-14, 3-chome,
Higashi Gotanda, Shinagawa-ku,
Tokyo, 141-0022 Japan
Phone: +81.3.6743.7890
Fax: +81.3.6743.9800